[Bronchial inflammation during chronic bronchitis, importance of fenspiride].

Abstract

PATHOPHYSIOLOGY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD): Chronic inflammation of the upper airways, pulmonary parenchyma and pulmonary vasculature is the characteristic feature of COPD. Two mechanisms besides inflammation are also involved: oxidative stress and imbalance between proteinases and antiproteinases. Cellular infiltration of the upper airways involved neutrophils, macrophages, T lymphocytes and eosinophils. Inflammatory mediators appear to play a crucial role in the interaction between inflammation and obstruction. PROPERTIES OF FENSPIRIDE: A nonsteroidal drug, fenspiride, exhibits interesting properties documented in vitro: anti-bronchoconstriction activity, anti-secretory activity, and anti-inflammatory activity (reduction in the activity of phospholipase A2 and release of proinflammatory leukotriens). Two french clinical trials have studied the efficacy of fenspiride in patients with acute excerbation or stable COPD and have demonstrated an improvement in the group treated with fenspiride compared with the placebo group.

• Authors: B Melloni
• Journal: Presse medicale (Paris, France : 1983) (Presse Med) Vol. 31 Spec No 1 Pg. HS11-5 (Sep 2002) ISSN: 0755-4982 [Print] France
• Vernacular Title: Inflammation bronchique au cours de la bronchite chronique, intérêt du fenspiride.
• PMID: 12378968 (Publication Type: Journal Article)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Inflammation Mediators
• Leukotriene Antagonists
• Spiro Compounds
• Phospholipases A
• Phospholipases A2
• fenspiride

Topics

• Animals
• Anti-Inflammatory Agents, Non-Steroidal (adverse effects, therapeutic use)
• Bronchitis, Chronic (drug therapy, immunology)
• Bronchoconstriction (drug effects)
• Clinical Trials as Topic
• Humans
• Immunity, Cellular (drug effects)
• In Vitro Techniques
• Inflammation Mediators (antagonists & inhibitors, immunology)
• Leukotriene Antagonists
• Phospholipases A (antagonists & inhibitors)
• Phospholipases A2
• Pulmonary Disease, Chronic Obstructive (drug therapy, immunology)
• Spiro Compounds (adverse effects, therapeutic use)